In Part 1, I discussed common misconceptions behind why pharmaceutical companies aren’t using data to improve clinical trials processes. Firstly, people often think that digital health solutions are young and unreliable – but in fact, there are options on the market that are incredibly robust and often unknown due to a crowded consumer market. Second, many executives believe that aggregating data points across multiple sources is cumbersome. That, too, is a misconception. In fact, there are companies...